Division of Medicinal Chemistry and Natural Products, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599-7568, USA.
J Med Chem. 2010 Aug 12;53(15):5716-26. doi: 10.1021/jm100508m.
Lacosamide ((R)-N-benzyl 2-acetamido-3-methoxypropionamide, (R)-1) is a low molecular weight anticonvulsant recently introduced in the United States and Europe for adjuvant treatment of partial-onset seizures in adults. In this study, we define the structure-activity relationship (SAR) for the compound's 3-oxy site. Placement of small nonpolar, nonbulky substituents at the 3-oxy site provided compounds with pronounced seizure protection in the maximal electroshock (MES) seizure test with activities similar to (R)-1. The anticonvulsant activity loss that accompanied introduction of larger moieties at the 3-oxy site in (R)-1 was offset, in part, by including unsaturated groups at this position. Our findings were similar to a recently reported SAR study of the 4'-benzylamide site in (R)-1 ( J. Med. Chem. 2010 , 53 , 1288 - 1305 ). Together, these results indicate that both the 3-oxy and 4'-benzylamide positions in (R)-1 can accommodate nonbulky, hydrophobic groups and still retain pronounced anticonvulsant activities in rodents in the MES seizure model.
拉科酰胺((R)-N-苄基 2-乙酰氨基-3-甲氧基丙酰胺,(R)-1)是一种低分子量抗惊厥药,最近在美国和欧洲被引入,用于辅助治疗成人部分发作性癫痫。在这项研究中,我们定义了该化合物 3-氧基部位的构效关系(SAR)。在 3-氧基部位放置小的非极性、非庞大的取代基,可使化合物在最大电休克(MES)癫痫发作试验中具有显著的抗癫痫保护作用,其活性与(R)-1 相似。在(R)-1 中 3-氧基部位引入较大的基团会导致抗惊厥活性丧失,而在该位置包含不饱和基团在一定程度上弥补了这一损失。我们的发现与最近报道的(R)-1 的 4'-苄基酰胺部位的 SAR 研究相似( J. Med. Chem. 2010, 53, 1288 - 1305 )。总之,这些结果表明,(R)-1 的 3-氧基和 4'-苄基酰胺部位都可以容纳非庞大的疏水性基团,并且在 MES 癫痫发作模型中仍能在啮齿动物中保持显著的抗惊厥活性。